Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
34,778
datasets available to search
ShareScore release 0.9.0
Dataset results
34,778 results for “Diseases”
MD preview for: Fighting Celiac Disease: Improvement of pH Stability of Cathepsin L In Vitro by Computational Design
<p>Dataset structure:<br> This is MD preview (some initial and final files, along with light versions of principal MD trajectories) for wild-type (WT) and acidophilic mutant (V277A) cathepsin L versions. Each folder contains three variants of pH calculations:</p> <ul> <li>pH 7</li> <li>pH 2 (considering all ionizable residues)</li> <li>pH 2 (considering only His 275)</li> </ul> <p>See paper text for details.</p> <p>Each subfolder contains seven MD-related files:</p> <ul> <li>md.mdp: Gromacs options file</li> <li>topol.top: system topology, including ionization states of the charged residues</li> <li>em.gro: system coordinates before MD</li> <li>md.gro: system coordinates after MD</li> <li>md.tpr: Gromacs tpr file required for MD start</li> <li>md_view.gro: system coordinates after MD without water and ions. Required for MD preview using the next trajectory file</li> <li>md_view.xtc: "light" MD trajectory file without water and ions with coordinates saved each 100 ps (gmx trjconv "-dt 100" option). Use two latter files for MD preview in software like VMD or Pymol.</li> </ul>
A five-sensor IMU-based Parkinson's disease patient and control dataset including three activities of daily living
<p class="MsoNormal">Parkinson's disease is an often-debilitating progressive neurological condition leading to loss of motor control. This dataset contains kinematic sensor data from two groups: one containing 15 patients with Parkinson's disease, and a control group of 19 participants without any known neurological condition. Participant ages ranged from 40–85, 21 were male, and 13 were female. The participants wore five 9-axis Inertial Measurement Units (IMUs) – one on each upper arm, each lower arm, and on their head. They were asked to perform a calibration pose, followed by three activities: making toast, putting on a cardigan, and unlocking and opening a door, with each activity repeated three times. The IMUs recorded time-series acceleration and orientation data from the moment where the participant was instructed to begin the activity (inception of the idea to act), through to the activity's completion. This dataset is planned for use in intent-sensing studies for assistive device control but is also applicable for activity recognition.</p>
Data from: Developmental exposure to the Parkinson's disease-associated organochlorine pesticide dieldrin alters dopamine neurotransmission in α-synuclein pre-formed fibril (PFF)-injected mice
<p>Parkinson's disease (PD) is the fastest-growing neurological diseases worldwide, with increases outpacing aging and most rapid in recently industrialized areas, suggesting the role of environmental factors. Together, epidemiological studies, post-mortem analysis and mechanistic studies suggest that exposure to persistent organic pollutants, including the organochlorine pesticide dieldrin, increases PD risk. In mouse models, developmental dieldrin exposure causes male-specific exacerbation of neuronal susceptibility to MPTP and synucleinopathy. Specifically, developmental dieldrin exposure induces male-specific exacerbation of toxicity in the α-synuclein (α-syn) pre-formed fibril (PFF) model with increased deficits in striatal dopamine (DA) turnover and motor deficits on the challenging beam. Here, we hypothesized that alterations in DA handling contribute to the observed changes and assessed vesicular monoamine transporter 2 (VMAT2) function and DA release in this dieldrin/PFF two-hit model. Female C57BL/6 mice were exposed to 0.3 mg/kg dieldrin or vehicle every 3 days by feeding, starting at 8 weeks of age by ingestion and continuing throughout breeding, gestation, and lactation. Male offspring from independent litters underwent unilateral, intrastriatal injections of α-syn PFFs at 12 weeks of age and vesicular <sup>3</sup>H-DA uptake assays and fast-scan cyclic voltammetry (FSCV) were performed at 4 months post-PFF injection. We observed a dieldrin-induced increase in DA release in striatal slices in PFF-injected animals, but no change in VMAT2 activity. These results suggest that developmental dieldrin exposure increases a compensatory response to synucleinopathy-triggered striatal DA loss and supports our hypothesis that alterations in DA handling may underly the observed exacerbation of PFF-induced deficits in motor behavior and DA turnover.</p>
MMiKG: A Knowledge Graph-based Platform for Path Mining of Microbiota-Mental Diseases Interactions
<p><strong>The original datasets released in MMiKG, containing relevant information like PMID of labels and relations (triples).</strong></p> <p><strong>Background:</strong></p> <p>Gut microbiota has been demonstrated to be crucial in gut-brain axis. In this research, knowledge graphs was leveraged to aggregate and assimilate relevant information on the microbiome-gut-brain axis and its intricate relationships with mental diseases and formed a knowledge graph platform named MMiKG</p> <p> ► <strong>Advantages of MMiKG:</strong></p> <ul> <li> Assist users in semantic search and visualization operations</li> <li> Make the scattered knowledge machine-readable and interpretable</li> <li> Boost users’ confidence in the accuracy of the information</li> <li> Support better decision-making</li> </ul> <p> ► <strong>What users can do with MMiKG:</strong></p> <ul> <li>Integrate diverse resources</li> <li>Infer potential associations between gut microbiota and mental diseases</li> </ul> <p><strong>Tools:</strong></p> <p>MMiKG contains '770' entities and '1,257' triples among them. These items cover '20' common mental illnesses, '270' types of gut microbes, and '480' distinct intermediates.</p> <p> ► <strong>MMiKG's original data includes two folders:</strong></p> <p> ♦ The labels folder:</p> <ul> <li>Present information of each entity’s 'Id', 'Name', 'Degree', 'Type'</li> <li>'Disease.csv', 'Intermediate.csv', 'Microbiota.csv</li> </ul> <p> ♦ The relationships folder: </p> <ul> <li>Present information of 'SourceId', 'TargetId', 'Number', 'Reference PMID'</li> <li>'Disease.csv', 'Intermediate.csv', 'Microbiota.csv' </li> </ul>
PI3K block restores age-dependent neurovascular coupling defects associated with cerebral small vessel disease
<p class="MsoNormal">Neurovascular coupling (NVC), a vital physiological process that rapidly and precisely directs localized blood flow to the most active regions of the brain, is accomplished in part by the vast network of cerebral capillaries acting as a sensory web capable of detecting increases in neuronal activity and orchestrating the dilation of upstream parenchymal arterioles. Here, we report a <em>Col4a1</em> mutant mouse model of cerebral small vessel disease (cSVD) with age-dependent defects in capillary-to-arteriole dilation, functional hyperemia in the brain, and memory. The fundamental defect in aged mutant animals was the depletion of the minor membrane phospholipid phosphatidylinositol 4,5 bisphosphate (PIP<sub>2</sub>) in brain capillary endothelial cells, leading to the loss of inwardly rectifier K<sup>+</sup> (Kir2.1) channel activity. Blocking phosphatidylinositol-3-kinase (PI3K), an enzyme that diminishes the bioavailability of PIP<sub>2</sub> by converting it to phosphatidylinositol (3,4,5)-trisphosphate (PIP<sub>3</sub>), restored Kir2.1 channel activity, capillary-to-arteriole dilation, and functional hyperemia. In longitudinal studies, chronic PI3K inhibition also improved the memory function of aged <em>Col4a1</em> mutant mice. Our data suggest that PI3K inhibition is a viable therapeutic strategy for treating defective NVC and cognitive impairment associated with cSVD.</p>
Identification of Potential JNK3 Inhibitors Through Virtual Screening, Molecular Docking And Molecular Dynamics Simulation as Therapeutics for Alzheimer's Disease
<p>Alzheimer's disease (AD) is a complex neurological disorder without effective treatment. One factor in its development is c-Jun N-terminal kinases (JNKs), a type of protein related to brain function. JNK3, found mainly in the brain, contributes to AD by promoting brain abnormalities. Current research aims to create new JNK3 inhibitors for AD treatment using a virtual screening method. A database of compounds was filtered, and five potential compounds were identified with better scores than a reference. These compounds underwent simulations and energy calculations, showing stability and potential as JNK3 inhibitors.</p>
Associations of serum uric acid with cardiovascular disease risk factors: a retrospective cohort study in Southeastern China
<p class="MsoNormal"><span>Objective: To evaluate the associations between serum uric acid (SUA) levels and cardiovascular disease (CVDs) risk factors, focusing on potential sex-specific differences.</span></p> <p class="MsoNormal"><span>Design: A retrospective cohort study.</span></p> <p class="MsoNormal"><span>Setting: A large community-based survey was conducted every two years from 2010 to 2018 in Hangzhou, Zhejiang Province, Southeastern China.</span></p> <p class="MsoNormal"><span>Participants: 6119 participants aged 40 years and above who underwent at least three times of physical examinations were enrolled. </span></p> <p class="MsoNormal"><span>Methods: Participants were categorized into four groups (Q1-Q4) based on baseline SUA quartiles within the normal range, with hyperuricemia (HUA) as the fifth group. The Q1 was the reference. By stratifying participants by gender, the relationships between SUA levels and systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), and total cholesterol (TC) were investigated using linear regression models in the generalized estimating equation (GEE). Additionally, the associations of elevated SUA levels and HUA with hypertension, hyperglycemia, and dyslipidemia were correspondingly examined using multivariate logistic regression models.</span></p> <p class="MsoNormal"><span>Results: After adjusting for confounding variables, we found positive associations between SUA levels and SBP, DBP, FBG, and TC in women, and with TC in men (P < 0.01). Likewise, Elevated SUA quartiles and HUA were linked to increased dyslipidemia risk in both sexes, and increased hyperglycemia risk only in women, with HRs (95%CI) of 1.64 (1.05-2.55) and 2.37 (1.47-3.81) in the Q4 and HUA group, respectively. Women with HUA had higher hypertension risk (HR=1.45, 95% CI 1.21-1.73), while no such association was observed in men. Stratified analyses revealed significant associations between elevated SUA levels and CVDs risk factors in postmenopausal and non-obese women.</span></p> <p class="MsoNormal"><span>Conclusions: Elevated SUA levels increase the risk of dyslipidemia in both sexes. SUA levels within normal-range and HUA are positively associated with hyperglycemia and hypertension in postmenopausal women, but not in men.</span></p>
Bioimpedance phase angle as a prognostic tool in late-onset pompe disease: a single-centre prospective study with a 15-year follow-up
<p>We reported the long-term follow-up of a population of Late onset Pompe disease treated with enzyme replacement therapy. Among predictors of treatment effectiveness and prognosis, we include body composition assessment by bioelectrical vectorial impedance.</p> <p><strong>Methods. </strong>In this single Centre, prospective study, we evaluate the response to enzyme replacement therapy in 15 patients (7 males) with LOPD in different stages of disease, aged 49.4+16.1, followed-up for 15 years. Treatment response was measured by the six-minute walking test, vital capacity in supine and upright position, respiratory muscle strength, muscle MRI, manual muscle testing. We investigated the usefulness of Body Impedance Vectorial Analysis for serial body composition assessment.</p> <p><strong>Results (in brief). </strong>Although most patients with LOPD benefit from long-term treatment, some secondary decline may occur after the first 3-5 years. Some nutritional (lower body mass index, higher fat free mass, higher phase angle) and disease parameters (higher creatinine and shorter disease duration at the beginning of treatment) seem to predict a better motor outcome. Lower Phase Angle may reflect loss of integrity of skeletal muscle membranes, resulting from lysosomal and autophagosomal dysregulation; this leads to treatment mis-targeting, and thus to worse treatment response, and ultimately to whole cell damage. Indeed, the muscle is one of the tissue with the highest rate of autophagosome formation and degradation. </p>
Dataset: Disease-associated KCNMA1 variants decrease circadian clock robustness in channelopathy mouse models
<p><em>KCNMA1</em> encodes the voltage- and calcium-activated K<sup>+</sup> (BK) channel, which regulates suprachiasmatic nucleus (SCN) neuronal firing and circadian behavioral rhythms. Gain-of-function (GOF) and loss-of-function (LOF) alterations in BK channel activity disrupt circadian behavior, but the effect of human disease-associated <em>KCNMA1</em> channelopathy variants has not been studied on clock function. Here, we assess circadian behavior in two GOF and one LOF mouse lines. Heterozygous <em>Kcnma1</em><sup>N999S/WT</sup> and homozygous <em>Kcnma1</em><sup>D434G/D434G</sup> mice are validated as GOF models of paroxysmal dyskinesia (PNKD3), but whether circadian rhythm is affected in this hypokinetic locomotor disorder is unknown. Conversely, homozygous LOF <em>Kcnma1</em><sup>H444Q/H444Q </sup>mice do not demonstrate PNKD3. We assessed circadian behavior by locomotor wheel running activity. All three mouse models were rhythmic, but <em>Kcnma1</em><sup>N999S/WT</sup> and <em>Kcnma1</em><sup>D434G/D434G</sup> showed reduced circadian amplitude and decreased wheel activity, corroborating prior studies focused on acute motor coordination. In addition, <em>Kcnma1</em><sup>D434G/D434G</sup> mice had a small decrease in period. However, the phase-shifting sensitivity for both GOF mouse lines was abnormal. Both <em>Kcnma1</em><sup>N999S/WT</sup> and <em>Kcnma1</em><sup>D434G/D434G</sup> mice displayed increased responses to light pulses and took fewer days to re-entrain to a new light:dark cycle. In contrast, the LOF <em>Kcnma1</em><sup>H444Q/H444Q </sup>mice showed no difference in any of the circadian parameters tested. The enhanced sensitivity to phase-shifting stimuli in <em>Kcnma1</em><sup>N999S/WT</sup> and <em>Kcnma1</em><sup>D434G/D434G</sup> mice was similar to other <em>Kcnma1</em> GOF mice. Together with previous studies, these results suggest that increasing BK channel activity decreases circadian clock robustness, without rhythm ablation.</p>
Association of fat-to-muscle ratio with non-alcoholic fatty liver disease: a single-centre retrospective study
<p><strong>Objectives</strong>: Sarcopenia is a known risk factor for non-alcoholic fatty liver disease (NAFLD). Studies evaluating the association between the fat-to-muscle ratio (FMR) and NAFLD are limited. Therefore, the aim of our study was to investigate the association between FMR and NAFLD.</p> <p><strong>Design:</strong> A retrospective study was conducted on the individuals who underwent health examination in Wuhan Union Hospital between January 2020 and November 2021. Clinical data were collected from electronic medical records.</p> <p><strong>Setting:</strong> Our study was conducted in a hospital in China.</p> <p><strong>Participants:</strong> A total of 1,592 participants aged ≥40 years who underwent body composition analysis and liver ultrasonography were retrospectively reviewed.</p> <p><strong>Primary outcome measures:</strong> Liver ultrasonography was used to assess liver steatosis, and the Fibrosis-4 Index (FIB-4) was used to calculate the risk scores for liver fibrosis. The 10-year atherosclerotic cardiovascular disease (ASCVD) risk prediction model was used to calculate ASCVD risk scores.</p> <p><strong>Results:</strong> The FMR was significantly higher in individuals with NAFLD than in those without NAFLD (P<0.001). The prevalence of NAFLD gradually increased from FMR tertile 1 (reference) to tertile 2 (OR=1.49, 95% CI: 1.13–1.97) and tertile 3 (OR=2.85, 95% CI: 2.08–3.90). In addition, patients with NAFLD in FMR tertile 3 had a significantly higher risk of liver fibrosis (OR=4.48, 95% CI: 2.12–9.50) and ASCVD (OR=4.63, 95% CI: 2.62–8.19) than those in FMR tertile 1 after adjustment for multiple confounders.</p> <p><strong>Conclusion:</strong> In this study, we found a significant association between FMR and NAFLD. A higher FMR indicates a higher risk of NAFLD in the study population and a higher risk of liver fibrosis and ASCVD in NAFLD patients.</p>
Impacts of hurricanes and disease on Diadema antillarum in shallow water reef and mangrove locations in St John, USVI
<p>Number of Diadema antillarum per 10x2 m2 transect at 9 reef sites and 3 mangrove sites in St John USVI from 2017-2023</p>
The Association of Dry Eye Disease with Functional Visual Acuity and Quality of Life
<p>Background: Dry eye disease (DED) is a common chronic condition with increasing prevalence. Standard discriminative visual acuity is not reflective of real-world visual function as patients can achieve normal acuities by blinking. Methods: Participants recruited from a tertiary referral eye center were divided into 2 groups – severe DED (with significant, central staining) and comparison group with mild DED (absence of such staining). FVA in both groups were assessed using DryeyeKT mobile application and Impact of Vision Impairment (IVI) questionnaire to assess quality of life (QOL). Results: Among 78 participants (74.4% women), 30 (38.5%) had severe DED and 48 (61.5%) milder DED. In women, severe DED produced significantly worse FVA of 0.53 ± 0.20 vs. 0.73 ± 0.30 in comparison group (p = 0.0064). FVA decreased with increasing age, significant inverse correlation (r = -0.55). A poorer FVA =<0.6 was seen in older patients (68.2 years ± 7.68) vs. FVA > 0.6 in younger patients (58.9 years ± 10.7), p <0.05. When<strong> </strong>adjusting for age, FVA was still 0.107 lower in the severe DED group, p < 0.05. There was significant difficulty in performing specific daily activities in the severe DED group, after adjusting for age, gender and FVA. Conclusions: FVA is reduced in severe DED and older people. Severe DED significantly impacts certain QOL. However, no significant relationship was found between FVA and QOL. FVA is not the only reason for the compromise of health-related QOL in severe dry eye.</p>
Machine learning-based q-RASAR approach for the in silico identification of novel multi-target inhibitors against Alzheimer's disease
<p>In the present research, we propose a novel approach, termed the Machine Learning (ML)-Based q-RASAR (quantitative read-across structure-activity relationship) method, for the identification of potential multi-target inhibitors against AD. The q-RASAR effectively combines the principles of both read-across and 2D QSAR approaches. As a result, it is imperative to take into account similarity-related aspects in the process of developing q-RASAR models. In this investigation, we have implemented ML-based q-RASAR modeling against seven major targets (AChE, BuChE, BACE1, 5-HT6, CDK-5 enzymes, Amyloid precursor protein, and Tau aggregation) of AD using the initially selected features in 2D QSAR models for the identifications of novel multitarget inhibitors. The models were individually used to check the applicability domain of a pool of 407270 natural products (NPs) obtained from the COCONUT database (<a href="https://coconut.naturalproducts.net/download">https://coconut.naturalproducts.net/download</a>) and provided prioritized compounds for experimental detection of their performance as anti-Alzheimer's drugs. Furthermore, we have also developed the q-RASAAR (quantitative read-across structure-activity-activity relationship) and selectivity-based q-RASAR models to explore the most important features contributing to the dual inhibition against the respective targets. Furthermore, we have applied seven distinct machine learning algorithms to enhance the predictive abilities of q-RASAR and q-RASAAR models. Moreover, we have also developed the univariate q-RASAR model, with the RA function as the primary independent variable. Moreover, molecular docking experiments have been conducted to gain insights into the atomic-level molecular interactions between ligands and enzymes. These observations are then juxtaposed with the structural characteristics obtained from models that elucidate the mechanistic aspects of binding events. These proposed models may serve as valuable tools for pinpointing crucial molecular attributes when designing potential drugs for Alzheimer's therapy through the rational design of multi-target inhibitors.</p>
Assessing the Maturity level of Wearable Sensors for Home Monitoring in Parkinson's Disease through Evidence Evaluation Levels (EEL) and User Experience: A Comprehensive Review
<p>Source files for the PRISMA diagram and Figure 1 of the comprehensive review: Assessing the Maturity level of Wearable Sensors for Home Monitoring in Parkinson’s Disease through Evidence Evaluation Levels (EEL) and User Experience</p>
Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease
ClinicalTrials.gov study NCT04332991. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee
ClinicalTrials.gov study NCT01221441. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease
ClinicalTrials.gov study NCT00939822. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Sildenafil for Chronic Obstructive Pulmonary Disease
ClinicalTrials.gov study NCT00104637. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
ClinicalTrials.gov study NCT03385239. IPD Sharing: NO. Countries: 2. Publications: 1.
Support for Physical Activity in Everyday Life With Parkinson's Disease
ClinicalTrials.gov study NCT05510739. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.